CHMP adopts positive opinion on ARIAD's Iclusig

The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Iclusig 15 mg film-coated tablets intended for the treatment of chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia. Iclusig was designated as an orphan medicinal product on March 2, 2010, the EMA noted. The applicant for this medicinal product is ARIAD Pharma.